Premium
Cannabinoid agonist shows promise for treating cannabis dependence
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30496
Subject(s) - cannabidiol , cannabis , cannabinoid , agonist , tetrahydrocannabinol , pharmacology , cannabis dependence , medicine , cannabinoid receptor , dronabinol , placebo , psychiatry , receptor , alternative medicine , pathology
Treatment with a cannabinoid agonist product containing tetrahydrocannabinol (THC) and cannabidiol (CBD) resulted in fewer days of illicit cannabis use compared with placebo in a 12‐week randomized trial of patients with cannabis dependence. Because of the high number of subjects who dropped out of the study, however, researchers stated that more studies are needed to evaluate the potential role of cannabinoid agonist therapy for cannabis dependence.